Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics

被引：35

作者：

Fukuno, Kenji ^{[1
]}

Hara, Takeshi ^{[1
]}

Tsurumi, Hisashi ^{[1
]}

Shibata, Yuhei ^{[1
]}

Mabuchi, Ryoko ^{[1
]}

Nakamura, Nobuhiko ^{[1
]}

Kitagawa, Junichi ^{[1
]}

Shimizu, Masahito ^{[1
]}

Ito, Hiroyasu ^{[2
]}

Saito, Kuniaki ^{[3
,4
]}

Moriwaki, Hisataka ^{[1
]}

机构：

[1] Gifu Univ, Grad Sch Med, Dept Internal Med 1, Gifu 5011194, Japan

[2] Gifu Univ, Grad Sch Med, Dept Informat Clin Med, Gifu 5011194, Japan

[3] Kyoto Univ, Human Hlth Sci, Grad Sch Med, Kyoto, Japan

[4] Kyoto Univ, Fac Med, Kyoto, Japan

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 05期

关键词：

Immunological tolerance; prognostic factor; L-tryptophan catabolism; acute myeloid leukemia; indoleamine 2,3-dioxygenase; CONTINUOUS DRIP INFUSION; LOW-DOSE CYTARABINE; TRYPTOPHAN CATABOLISM; T-CELL; DENDRITIC CELLS; CANCER; INHIBITION; SUPPRESSION; INDUCTION; ETOPOSIDE;

D O I：

10.3109/10428194.2014.953150

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze breakdown of the essential amino acid L-tryptophan. We applied reverse transcription-polymerase chain reaction (RT-PCR) to examine IDO mRNA expression in acute myeloid leukemia (AML) blasts, and investigated its clinical significance. We enrolled 62 patients with AML between April 2005 and March 2013. Bone marrow-derived mononuclear fractions were separated and extracted mRNA was amplified by PCR. RT-PCR showed that the bone marrow of 23 patients expressed IDO mRNA but not in 39. IDO mRNA expression did not significantly differ among cytogenetic risk profiles. The 3-year overall survival rates for patients with and without IDO mRNA expression were 39% and 74%, respectively (p < 0.005). The rates for patients with intermediate-risk cytogenetics with and without IDO mRNA expression were 16% and 70%, respectively (p < 0.005). The expression of IDO mRNA was associated with a poor prognosis of AML.

引用

页码：1398 / 1405

页数：8

共 50 条

[21] Upregulation of Indoleamine 2,3-Dioxygenase Enzymes in Leukemic Mesenchymal Stromal Cells (MSCs) Can Influence MSC/Acute Myeloid Leukemia Cell Cross Talk
Ciciarello, Marilena
Corradi, Giulia
Baldazzi, Carmen
Testoni, Nicoletta
Lemoli, Roberto Massimo
Cavo, Michele
Curti, Antonio
BLOOD, 2015, 126 (23)
[22] High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
Chamuleau, Martine E. D.
Van de Loosdrecht, Arjan A.
Hess, Corine J.
Janssen, Jeroen J. W. M.
Zevenbergen, Adri
Delwel, Ruud
Valk, Peter J. M.
Lowenberg, Bob
Ossenkoppele, Geri J.
BLOOD, 2007, 110 (11) : 142B - 142B
[23] Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-γ
Corm, Selim
Berthon, Celine
Imbenotte, Michel
Biggio, Valeria
Lhermitte, Michel
Dupont, Caroline
Briche, Isabelle
Quesnel, Bruno
LEUKEMIA RESEARCH, 2009, 33 (03) : 490 - 494
[24] High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
Chamuleau, Martine E. D.
de Loosdrecht, Arjan A. van
Hess, Corine J.
Janssen, Jeroen I. W. M.
Zevenbergen, Adri
Delwel, Ruud
Valk, Peter J. M.
Loewenberg, Bob
Ossenkoppele, Gert J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (12): : 1894 - 1898
[25] HIGH INDO (INDOLEAMINE 2,3-DIOXYGENASE) MRNA LEVEL IN BLASTS OF ACUTE MYELOID LEUKEMIC PATIENTS PREDICTS POOR CLINICAL OUTCOME
Chamuleau, M. E. D.
de Loosdrecht, A. A. van
Hess, C. J.
Zevenbergen, A.
Janssen, J. W. M.
Delwel, R.
Valk, P. J. M.
Lowenberg, B.
Ossenkoppele, G. J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 8 - 8
[26] Indoleamine 2,3-dioxygenase 1 alters the proportions of B cell subpopulations in the microenvironment of acute myeloid leukemia
Yu Yao
Yu-ying Liu
Jian-feng Li
Yun-shuo Chen
Lei Shi
Yang Shen
Li-li Yang
Qing Yang
Molecular Biomedicine, 6 (1):
[27] Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype
Arandi, Nargess
Ramzi, Mani
Safaei, Fatemeh
Monabati, Ahmad
BLOOD RESEARCH, 2018, 53 (04) : 294 - 298
[28] Quantitative molecular expression of the immunoregulatory enzyme indoleamine 2,3-dioxygenase in acute myeloid leukemia cells as a possible marker for minimal residual disease detection
Aluigi, Michela
Curti, Antonio
Ottaviani, Emanuela
Lucchetti, Giovanna
Salvestrini, Valentina
D'Addio, Alessandra
Trabanelli, Sara
Fiore, Francesca
Massaia, Massimo
Martinelli, Giovanni
Baccarani, Michele
Lemoli, Roberto M.
BLOOD, 2007, 110 (11) : 124B - 124B
[29] Prognostic value of the combination of serum l-kynurenine level and indoleamine 2,3-dioxygenase mRNA expression in acute myeloid leukemia
Hara, Takeshi
Matsumoto, Takuro
Shibata, Yuhei
Nakamura, Nobuhiko
Nakamura, Hiroshi
Ninomiya, Soranobu
Kitagawa, Junichi
Nannya, Yasuhito
Shimizu, Masahito
Ito, Hiroyasu
Saito, Kuniaki
Tsurumi, Hisashi
LEUKEMIA & LYMPHOMA, 2016, 57 (09) : 2208 - 2211
[30] Indoleamine 2,3-dioxygenase expression is correlated to prognosis in localized prostate cancer.
Ferreira, Janaina Mendes
Pontes-Junior, Jose
Matheus, Luiz Henrique Gomes
Sousa, Diego Mota
Lima, Amanda Eunice Ramos
Almeida, Robson Jose
Camacho, Cleber Pinto
Reis, Sabrina Thalita
Leite, Katia Ramos Moreira
Srougi, Miguel
Delle, Humberto
FASEB JOURNAL, 2018, 32 (01):

← 1 2 3 4 5 →